Adage Capital Partners GP L.L.C. Sells 4,637,930 Shares of Savara Inc (NASDAQ:SVRA)

Adage Capital Partners GP L.L.C. decreased its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 68.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,115,771 shares of the company's stock after selling 4,637,930 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 1.23% of Savara worth $6,495,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in SVRA. Geode Capital Management LLC grew its stake in shares of Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock valued at $11,564,000 after buying an additional 264,825 shares in the last quarter. Vanguard Group Inc. raised its holdings in Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after buying an additional 365,959 shares during the last quarter. Barclays PLC raised its position in shares of Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company's stock worth $979,000 after acquiring an additional 158,244 shares during the last quarter. SG Americas Securities LLC increased its holdings in Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock worth $158,000 after purchasing an additional 6,330 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Savara by 23.9% in the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company's stock valued at $295,000 after acquiring an additional 13,420 shares during the period. Institutional investors own 87.93% of the company's stock.

Savara Trading Up 4.3 %

Shares of SVRA stock traded up $0.14 on Friday, hitting $3.40. 706,717 shares of the stock traded hands, compared to its average volume of 1,297,425. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market capitalization of $586.95 million, a PE ratio of -7.91 and a beta of 0.52. The firm's 50-day moving average price is $2.82 and its two-hundred day moving average price is $3.06. Savara Inc has a twelve month low of $2.26 and a twelve month high of $5.31.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. As a group, analysts anticipate that Savara Inc will post -0.45 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Savara presently has a consensus rating of "Moderate Buy" and an average target price of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.